APP and Alzheimer disease: However, in AD-mouse models (like APP/PS1), a reduction of blood-plasma level of Aβ42 serves as a good biomarker for evaluating the efficacy of an applied condition that aims at preventing/inhibiting the progression of AD-related brain pathologies [34].